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t Patient is female: all other patients are male.
and fixed tissue macrophages rely on the opsonic properties of FN to enhance their phagocytic capabilities. 8 This ubiquitous molecule has many biologic functions, including cell-to-cell and cell-to-substratum adhesion. 9, 16, 23, 35 This adhesion is mediated through binding sites on fibronectin for macromolecules, like collagen, 5 fibrinogen, 32 actin, 1012 and Clq," and also for bacteria. 13 The metastatic potential of neoplastic tissues might even be regulated in part by the fibronectin concentration in the cellular environment. 16 Clinical investigations have demonstrated that patients with carcinoma of the breast may have increased levels of plasma fibronectin. 4 In contrast, decreased fibronectin levels have been observed in patients after trauma, sepsis, or burn. 14, 30 Because alterations in circulating fibronectin levels might induce changes in the host defense mechanisms, we investigated plasma fibronectin concentrations in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC), a population known to have recurrent microbial infections attributed, in part, to impaired chemotaxis 31 and macrophage phagocytosis. 20 For the fibronectin measurements, we adapted a turbidimetric immunoassay for use with commercially available reagents and a centrifugal analyzer.
Materials and Methods

Patients and Controls
All 24 patients included in this study were referred to The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston and fulfilled the criteria for the diagnosis of AIDS or ARC established by the Centers for Disease Control. 6 Nineteen patients had AIDS and five had ARC (Table 1) . Seventy-four ageand gender-matched healthy blood donors (40 men, 34 women) served as controls. Plasma specimens were prepared from sodium citrate anticoagulated blood within one hour of phlebotomy and immediately frozen at -20 °C.
Turbidimetric Fibronectin Assay
The assay used is based on the method described by North and colleagues, 22 using a commercially available test kit for a turbidmetric fibronectin immunoassay (Boehringer-Mannheim, Indianapolis, IN) in conjunction with the Cobas-BIO® programmable centrifugal analyzer (Roche Diagnostics, Nutley, NJ). The kit included antihuman fibronectin, standard fibronectin solutions (45-322 mg/L), and diluent buffer (100 mmol/L phosphate buffer, pH 7.4, containing 3% polyethylene glycol). Further dilutions of the kit standards were prepared (70 mg/L, 110 mg/L, 290 mg/L) for analytic evaluation of the assay. Plasma from 40 healthy blood donors was pooled for a normal control or diluted fourfold with diluent buffer and used as a low control.
All reagents were warmed in a 30 °C water bath for at least 15 minutes before use. Three microliters of fibronectin standard, patient, or normal or low control plasma was automatically mixed with 370 fiL of antifibronectin, diluted 1:10 in diluent buffer. The absorbance at 340 nm was measured after 1 and 10 minutes incubation at 30 °C. Plasma fibronectin concentrations were calculated from an internally stored standard curve. Samples with fibronectin values greater than 322 mg/L were appropriately diluted to measure within the linear portion of the standard curve.
Results
A standard curve for fibronectin concentrations ranging from 45 to 322 mg/L is shown in Figure 1 . The assay showed a within-run precision of 2.1%, 2.3%, 1.8%, and 
Discussion
Optimal function of the reticuloendothelial system requires the presence of soluble opsonins in addition to effector cells. 24, 25 Because fibronectin serves as an opsonic protein that enhances the phagocytic clearance of macromolecules 33 and certain bacteria, 13 ' 26 the evaluation of fibronectin concentrations in a group of immunodeficient patients with a characteristic inability to resist fatal oportunistic infections appeared to be of special interest.
The conditions of patients included in this study represent progressive stages of AIDS, with or without current infections. Patients with ARC/AIDS showed no significant difference in the amounts of plasma fibronectin compared with those in the control group, the values for the healthy men and women being in good agreement with those reported previously with the use of various methods. 2,7,I9,21 Only one patient had a slightly increased fibronectin value (479 mg/L) compared with the controls. Therefore, it is doubtful that soluble fibronectin contributes to the inability of these immunodeficient patients to control infections by opportunistic organisms. However, because significant numbers of people with AIDS have bacterial and fungal pneumonias develop, it is interesting to speculate that alveolar macrophage function may be compromised in an environment inaccessible to circulating plasma fibronectin. If retoviral infection of helper/inducer lymphocytes ultimately inhibits the endogenous production of fibronectin by macrophages, as in vitro studies have indicated, 1, 33 the phagocytic clearance of pathogenic microorganisms from the circulation may be ineffective. The observation reported by others 20 that antimicrobial activity of macrophages obtained from patients with AIDS could be reconstituted with immune gamma interferon would support this assumption. Conversely, it could be argued that fibronectin plays no opsonic role in the phagocytosis of those pathogenic organisms affecting patients with AIDS.
Although the determination of fibronectin levels in people with AIDS/ARC is seemingly of little value to the diagnosis or therapeutic management of this syndrome, the simplified assay described herein could be used for patients with other pathologic conditions in whom measurement of plasma fibronectin has been shown to be significant.
The availability of commercial reagents, the small amount of test plasma required to perform this assay, and the automation afforded by a centrifugal analyzer make this test readily adaptable to use in routine clinical laboratories.
